Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4072-4079
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4072
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4072
Figure 4 Changes in the status of hepatitis B e antigen (HBeAg) and anti-HBe after treatment with lamivudine and adefovir in patients with positive HBeAg.
Before treatment with lamivudine, HBeAg was positive in 39 patients. After one year of treatment, 7 patients became HBeAg negative and 2 of these became anti-HBe positive. During treatment with lamivudine, 14 patients became HBeAg negative and 7 of these became anti-HBe positive. After development of viral breakthrough because of lamivudine-resistance, HBeAg reappeared in 8 of the 14 patients. HBeAg was positive in 33 patients before the treatment with adefovir. HBeAg became negative in 22 patients and 5 of them became anti-HBe positive after one year of treatment. The numerals in the boxes represent the number of patients according to the status of HBeAg and anti-HBe.
- Citation: Seo YS, Kim JH, Yeon JE, Park JJ, Kim JS, Byun KS, Bak YT, Lee CH. Antiviral efficacy of adefovir dipivoxil versus lamivudine in patients with chronic hepatitis B sequentially treated with lamivudine and adefovir due to lamivudine resistance. World J Gastroenterol 2007; 13(30): 4072-4079
- URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4072.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i30.4072